Filing Details
- Accession Number:
- 0001144204-14-014246
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-03-07 19:29:02
- Reporting Period:
- 2014-03-05
- Filing Date:
- 2014-03-07
- Accepted Time:
- 2014-03-07 19:29:02
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1088856 | Corcept Therapeutics Inc | CORT | Pharmaceutical Preparations (2834) | 770487658 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1419701 | L.p. Partners Venture Longitude | 800 El Camino Real Suite 220 Menlo Park CA 94025 | Yes | No | Yes | No | |
1430719 | Longitude Capital Associates, L.p. | 800 El Camino Real Suite 220 Menlo Park CA 94025 | No | No | Yes | No | |
1430720 | Longitude Capital Partners, Llc | 800 El Camino Real Suite 220 Menlo Park CA 94025 | No | No | Yes | No | |
1431159 | Juliet Bakker Tammenoms | Longitude Capital Management Co., Llc 800 El Camino Real, Suite 220 Menlo Park CA 94025 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2014-03-05 | 70,063 | $4.01 | 13,175,781 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-03-05 | 1,404 | $4.01 | 186,325 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-03-06 | 164,800 | $4.00 | 13,010,981 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-03-06 | 3,303 | $4.00 | 183,022 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-03-07 | 10,225 | $4.00 | 13,000,756 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-03-07 | 205 | $4.00 | 182,817 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Reflects sales of common stock executed in multiple transactions at prices ranging from $4.00 to $4.07. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
- Does not include warrants held by Longitude Venture Partners, L.P. ("LVP") to purchase 3,091,479 shares of common stock.
- Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital") and Juliet Tammenoms Bakker, all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors. Each of Longitude Capital and Ms. Tammenoms Bakker disclaims beneficial ownership of these securities except to the extent of their respective pecuniary interest therein.
- Does not include warrants held by Longitude Capital Associates, L.P. ("LCA") to purchase 26,583 shares of common stock.
- Reflects transactions and holdings of shares of common stock held of record by LCA. This report is jointly filed by LCA, Longitude Capital and Juliet Tammenoms Bakker, all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Tammenoms Bakker disclaims beneficial ownership of these securities except to the extent of their respective pecuniary interest therein.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $4.00 to $4.01. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.